Recent

% | $
Quotes you view appear here for quick access.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

tatensolo 7 posts  |  Last Activity: Apr 15, 2015 9:31 PM Member since: Jun 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Nice movement on solid volume

    by illini_in_iowa Apr 14, 2015 9:56 PM
    tatensolo tatensolo Apr 15, 2015 9:31 PM Flag

    Up big on high volume, Down on minimal volume. Like it!!

  • tatensolo tatensolo Apr 3, 2015 11:12 AM Flag

    I disagree. First to beartrap, the latest financing included NO warrants. The total diluted shares are something like 160M (120M issued + 40M warrantsI think, but not sure. Still a successful PhIII would put valuation for a takeout at over $500MM so a 3x from here in 18 months is very realistic, assuming PhIII is successful, which I think it will be. With regards to the financing, these biotech "angel" funds always require a big margin of safety before investing, nothing new. CYNAF would have loved better terms but they were obviously not available. The investing funds are at least reputable ones who tend to hold investment for longer term. They did not go to the vulture funds that fund biotechs with much longer odds of success at more onerous terms. I believe they did the right thing. They are fully funded now and can focus their attention 100% on PhIII. You may be right, it will possibly backtrack and you can re-enter at lower level, but unless there is some bad news along the way, we may have crossed the $1 level for good. GLTA.

  • Reply to

    Cup and handle continuation pattern?

    by r.frank Apr 2, 2015 4:06 PM
    tatensolo tatensolo Apr 2, 2015 5:30 PM Flag

    That's my thinking but more likely 18 months for the 3x. Need positive Ph III data for the big move in 2016. After that a sale or commercialization agreement would create more upside. CEO thinks co is worth $1B. That may be too much but a $750M sale would be reasonable, so additional 50% upside to $4-$5.

  • tatensolo tatensolo Apr 1, 2015 4:44 PM Flag

    AS you can see, the market reaction to the placement has been positive even though it was at a significant discount (~20%) to Monday's pps of USD 95c. I think the key is the quality of investors giving CYNAF their vote of confidence, like Napodano said. Look-up those investors, some well known early biotech funds. Now it all comes down to execution with the funding overhang gone. I believe pps will slowly trend up as Ph3 moves forward and of course will have step changes with each positive announcement as story gets further de-risked. Of course if Ph3 fails it's over, but clinical risk appears low and risk/reward profile attractive..

  • Reply to

    Too bad this company is just a one

    by drehmsm Mar 18, 2015 8:53 PM
    tatensolo tatensolo Mar 19, 2015 2:31 PM Flag

    This co is a gift. There is no better investment than a development stage microcap biotech with cash in the bank, low clinical risk, and a focused management team. If you know of another stock that can deliver a 5x in 18 months, please share. I follow all of Napodano#$%$ and this is by far my largest position because of the 3 things mentioned above. Among them "low clinical risk" being the most important one. It is not easy to find that combo. I invested heavily in Questcor back in '12, a "one trick pony" shorted by many but with one approved drug with large potential markets, lots of cash, and a smart CEO, and made out like a bandit. GLTA.

  • Reply to

    Get Those thumbs ready

    by baileysix Feb 2, 2015 10:11 PM
    tatensolo tatensolo Feb 6, 2015 2:30 PM Flag

    Meant to type "go up", not "group". I personally do not believe they will try to go it alone. Building a sales force and commercializing a product is a very expensive and time consuming and difficult task. I strongly believe they will partner or sell out. Either way I will be happy. By the way, nice pop today and relatively high volume.

  • Reply to

    Get Those thumbs ready

    by baileysix Feb 2, 2015 10:11 PM
    tatensolo tatensolo Feb 3, 2015 4:46 PM Flag

    Look, if you investment thesis is a buyback, then good luck, that is never a sure thing. But CYNAF seems to have a proven product with a really convenient delivery method. I believe clinical risk is low and when it gets approved they will have the option to sell out or partner to commercialize and in either case the pps will group, which is what I care about. Just focus on them successfully following their clinical path to approval. With regards to Acorda, I think they where interested in CYNAF but CYNAF was not interested in selling out so early. CYNAF believes they should command a $1B buyout price. Acorda was not willing to pay that kind of $. And I do agree that phase II should have been bigger but now "we are onto Phase III". GLTA.

QCOR
93.600.00(0.00%)Aug 14 4:00 PMEDT